Suboptimal outcomes and treatment burden of anti-vascular endothelial growth factor treatment for diabetic macular oedema in phakic patients.

Christina Rennie Andrew John LoteryJo PayneMoushmi SinghFaruque D Ghanchi

Published in: Eye (London, England) (2023)

Data confirm previous real world evidence around response to anti-VEGF treatment, importance of baseline VA and frequency of injections in predicting outcomes in a UK setting. Continuing treatment beyond 6 months in suboptimal responders imposes unnecessary treatment burden without significant change in VA. In suboptimal responders, consideration of early switch to longer acting steroid treatments may help to reduce treatment burden, whilst maintaining or improving vision.

Keyphrases

vascular endothelial growth factor
type diabetes
endothelial cells
machine learning
end stage renal disease
metabolic syndrome
newly diagnosed
chronic kidney disease
combination therapy
electronic health record